Alberto Sada Japp

Alberto Sada Japp

Auto-generated profile, based on publicly available information

Alberto Sada Japp

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
SNSon Nguyen
Son Nguyen
CDClaire Deleage
Claire Deleage
SDSamuel Darko
Samuel Darko
ARAmy Ransier
Amy Ransier
DTDuc P. Truong
Duc P. Truong
MBMichael R. Betts
Michael R. Betts
Elite control of HIV replication is linked to polyfunctional lymphoid CD8 + T cells that lack overt cytolytic activity and home to B cell follicles.

16 September 2019 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
DFDavid C. Fajgenbaum
David C. Fajgenbaum
RLRuth-Anne Langan
Ruth-Anne Langan
AJAlberto Sada Japp
Alberto Sada Japp
HPHelen L. Partridge
Helen L. Partridge
SPSheila K. Pierson
Sheila K. Pierson
TUThomas S. Uldrick
Thomas S. Uldrick
BACKGROUND. Idiopathic multicentric Castleman disease (iMCD) is a hematologic illness involving cytokine-induced lymphoproliferation, systemic inflammation, cytopenias, and life-threatening multi-organ dysfunction. The molecular underpinnings of interleukin-6 (IL-6) blockade–refractory patients remain unknown; no targeted therapies exist. In this study, we searched for therapeutic targets in IL-6 blockade–refractory iMCD patients with the thrombocytopenia, anasarca, fever/elevated C-reactive protein, reticulin myelofibrosis, renal dysfunction, organomegaly (TAFRO) clinical subtype. METHODS. We analyzed tissues and blood samples from 3 IL-6 blockade–refractory iMCD-TAFRO patients. Cytokine panels, quantitative serum proteomics, flow cytometry of PBMCs, and pathway analyses were employed to identify novel therapeutic targets. To confirm elevated mTOR signaling, a candidate therapeutic target from the above assays, immunohistochemistry was performed for phosphorylated S6, a read-out of mTOR activation, in 3 iMCD lymph node tissue samples and controls. Proteomic, immunophenotypic, and clinical response assessments were performed to quantify the effects of administration of the mTOR inhibitor sirolimus. RESULTS. Studies of 3 IL-6 blockade–refractory iMCD cases revealed increased CD8+ T cell activation, VEGF-A, and PI3K/Akt/mTOR pathway activity. Administration of sirolimus substantially attenuated CD8+ T cell activation and decreased VEGF-A levels. Sirolimus induced clinical benefit responses in all 3 patients with durable and ongoing remissions of 66, 19, and 19 months. CONCLUSION. This precision medicine approach identifies PI3K/Akt/mTOR signaling as the first pharmacologically targetable pathogenic process in IL-6 blockade–refractory iMCD. Prospective evaluation of sirolimus in treatment-refractory iMCD is planned (NCT03933904). FUNDING. This study was supported by the Castleman’s Awareness & Research Effort/Castleman Disease Collaborative Network, Penn Center for Precision Medicine, University Research Foundation, Intramural NIH funding, and the National Heart Lung and Blood Institute.

10 December 2020 in Cell
Verified
Journal Article
Closed access
MBMarcus Buggert
Marcus Buggert
LVLaura A. Vella
Laura A. Vella
SNSon Nguyen
Son Nguyen
VWVincent H. Wu
Vincent H. Wu
ZCZeyu Chen
Zeyu Chen
MBMichael R. Betts
Michael R. Betts

20 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
SOSarah A. Overall
Sarah A. Overall
JTJugmohit S. Toor
Jugmohit S. Toor
SHStephanie Hao
Stephanie Hao
MYMark Yarmarkovich
Mark Yarmarkovich
SOSara M. O’rourke
Sara M. O’rourke
NSNikolaos G. Sgourakis
Nikolaos G. Sgourakis
Peptide exchange technologies are essential for the generation of pMHC-multimer libraries used to probe diverse, polyclonal TCR repertoires in various settings. Here, using the molecular chaperone TAPBPR, we develop a robust method for the capture of stable, empty MHC-I molecules comprising murine H2 and human HLA alleles, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. Alternatively, catalytic amounts of TAPBPR can be used to exchange placeholder peptides with high affinity peptides of interest. Using the same system, we describe high throughput assays to validate binding of multiple candidate peptides on empty MHC-I/TAPBPR complexes. Combined with tetramer-barcoding via a multi-modal cellular indexing technology, ECCITE-seq, our approach allows a combined analysis of TCR repertoires and other T cell transcription profiles together with their cognate antigen specificities in a single experiment. The new approach allows TCR/pMHC interactions to be interrogated easily at large scale.

7 May 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
RPRuth-Anne Langan Pai
Ruth-Anne Langan Pai
AJAlberto Sada Japp
Alberto Sada Japp
MGMichael Gonzalez
Michael Gonzalez
RRRozena F. Rasheed
Rozena F. Rasheed
MOMariko Okumura
Mariko Okumura
DFDavid C. Fajgenbaum
David C. Fajgenbaum
The TAFRO clinical subtype of idiopathic multicentric Castleman disease (iMCD-TAFRO) is a rare hematologic illness involving episodic disease flares of thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly (TAFRO) and progressive multiple organ dysfunction. We previously showed that the mTOR signaling pathway is elevated in lymph nodes of iMCD-TAFRO patients and that an mTOR inhibitor is effective in a small cohort of patients. However, the upstream mechanisms, cell types, and mediators involved in disease pathogenesis remain unknown. Here, we developed a targeted approach to identify candidate cellular drivers and mechanisms in iMCD-TAFRO through cellular and transcriptomic studies. Using paired iMCD-TAFRO PBMC samples collected during flare and remission, we identified T cell activation and alterations in NK cell and monocyte subset frequencies during iMCD-TAFRO flare. These changes were associated with increased Type I IFN (IFN-I) response gene signatures across CD8 + T cells, NK cells, and monocytes. Finally, we found that IFN-β stimulation of monocytes and T cells from iMCD-TAFRO patient remission samples induced increased mTOR activation compared with healthy donors, and this was abrogated with either mTORC1 or JAK1/2 inhibition. The data presented here support a potentially novel role for IFN-I signaling as a driver of increased mTOR signaling in iMCD-TAFRO.

23 May 2025 in Science Advances
Verified
Journal Article
Open access
Phillip SchielePhillip Schiele
Phillip Schiele
AJAlberto Sada Japp
Alberto Sada Japp
RSRegina Stark
Regina Stark
JSJoanna J. Sattelberg
Joanna J. Sattelberg
CNChristos Nikolaou
Christos Nikolaou
MFMarco Frentsch
Marco Frentsch
T cells and their effector functions, in particular the canonical cytotoxicity of CD8 + T cells involving perforin, granzymes, Fas ligand (FasL), and tumor necrosis factor related apoptosis inducing ligand (TRAIL), are crucial for tumor immunity. Here, we reveal a previously unidentified mechanism by which CD40L-expressing CD8 + T cells induce cytotoxicity in cancer cells. In murine models, up to 50% of tumor-specific CD8 + T cells expressed CD40L, and conditional CD40L ablation in CD8 + T cells alone led to tumor formation. Mechanistically, CD40L + CD8 + T cells can induce cell death in CD40-expressing cancer cells by triggering caspase-8 activation. We demonstrate that a gene signature for resistance to CD40 signaling–induced cell death strongly correlates with worse survival in different human cancer cohorts. Our results introduce CD40L as a rather counterintuitive, noncanonical cytotoxic factor that complements the capabilities of CD8 + T cells to combat cancers and has the potential to enhance the efficacy of immunotherapies.